We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+73.06%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$912M
AUM Growth
-$156M
Cap. Flow
-$257M
Cap. Flow %
-28.19%
Top 10 Hldgs %
35.78%
Holding
190
New
54
Increased
34
Reduced
35
Closed
53

Top Buys

Rank Stock Value
1
CRBP icon
Corbus Pharmaceuticals
CRBP
+$8.96M
2
CYTK icon
Cytokinetics
CYTK
+$8.91M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.6M
4
JBIO
Jade Biosciences
JBIO
+$8.03M
5
PYXS icon
Pyxis Oncology
PYXS
+$6.99M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$26.5M
2
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$21.4M
3
XHB icon
State Street SPDR S&P Homebuilders ETF
XHB
+$19.1M
4
NUVL
Nuvalent
NUVL
+$12.5M
5
IRON icon
Disc Medicine
IRON
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 39.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRYS icon
1
PUT
Krystal Biotech
KRYS
$9.88B
$66.7M 7.32%
375,000
-37,000
-9% -$5.14M
XBI icon
2
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$66.4M 7.28%
700,000
+150,000
+27% +$13.9M
CRNX icon
3
Crinetics Pharmaceuticals
CRNX
$8.86B
$30.1M 3.3%
643,751
-36,619
-5% -$1.43M
TARS icon
4
Tarsus Pharmaceuticals
TARS
$2.56B
$25.8M 2.83%
710,277
+191,758
+37% +$5.64M
CORT icon
5
PUT
Corcept Therapeutics
CORT
$10.2B
$25.1M 2.75%
994,500
+723,200
+267% +$17.1M
IRON icon
6
PUT
Disc Medicine
IRON
$2.83B
$24.7M 2.71%
+396,600
New +$25.7M
SLNO
7
DELISTED
Soleno Therapeutics
SLNO
$24.2M 2.65%
565,411
-24,832
-4% -$1.12M
CRBP icon
8
Corbus Pharmaceuticals
CRBP
$170M
$21.9M 2.41%
559,271
+363,372
+185% +$8.96M
AZN icon
9
CALL
AstraZeneca
AZN
$263B
$20.9M 2.3%
+154,600
New +$20.5M
ALNY icon
10
PUT
Alnylam Pharmaceuticals
ALNY
$36.3B
$20.4M 2.24%
136,700
+38,100
+39% +$6.36M
SRPT icon
11
Sarepta Therapeutics
SRPT
$1.66B
$19.7M 2.16%
152,278
+19,638
+15% +$2.41M
ALNY icon
12
CALL
Alnylam Pharmaceuticals
ALNY
$36.3B
$18.1M 1.98%
120,800
-48,900
-29% -$8.16M
KRYS icon
13
CALL
Krystal Biotech
KRYS
$9.88B
$17.8M 1.95%
100,000
– –
AMGN icon
14
CALL
Amgen
AMGN
$203B
$17.1M 1.87%
60,000
+25,000
+71% +$7.32M
VKTX icon
15
PUT
Viking Therapeutics
VKTX
$4.04B
$16.4M 1.8%
+200,000
New +$8.9M
BMEA icon
16
CALL
Biomea Fusion
BMEA
$90.4M
$16.1M 1.77%
1,077,600
+300,000
+39% +$4.94M
SRPT icon
17
CALL
Sarepta Therapeutics
SRPT
$1.66B
$15M 1.65%
116,100
-66,500
-36% -$8.15M
CRNX icon
18
PUT
Crinetics Pharmaceuticals
CRNX
$8.86B
$14.1M 1.54%
+300,400
New +$11.8M
MDGL icon
19
PUT
Madrigal Pharmaceuticals
MDGL
$12.6B
$13.7M 1.5%
+51,400
New +$12.1M
EYPT icon
20
PUT
EyePoint Inc
EYPT
$1.02B
$13.6M 1.49%
658,200
+375,000
+132% +$9.28M
BHVN icon
21
CALL
Biohaven
BHVN
$2.16B
$12.2M 1.34%
+223,700
New +$11.1M
BBIO icon
22
CALL
BridgeBio Pharma
BBIO
$16.5B
$12M 1.32%
+389,400
New +$13.2M
JBIO
23
Jade Biosciences
JBIO
$1.22B
$10.9M 1.19%
+10,513
New +$8.03M
LNTH icon
24
CALL
Lantheus
LNTH
$6.82B
$10.6M 1.16%
170,000
-100,000
-37% -$5.88M
SLRN
25
DELISTED
ACELYRIN
SLRN
$10.6M 1.16%
1,564,340
-426,665
-21% -$3.24M
1
2 3 4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Ikarian Capital held 190 positions worth $912M, down 15% from $1.07B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Ikarian Capital withdrew a net $257M in Q1 2024, closing 53 positions and reducing 35 holdings. Its most notable exit was argenx, an estimated $26.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 40% of assets, up from 32% a quarter earlier.

Against the trend, Ikarian Capital opened a new position in Alnylam Pharmaceuticals worth $7.7M.

  • Ikarian Capital's largest Q1 2024 buy was Alnylam Pharmaceuticals: 51,541 shares worth $7.7M.
  • Ikarian Capital added most to Corbus Pharmaceuticals in Q1 2024, an estimated $8.96M increase.
  • Ikarian Capital's biggest Q1 2024 reduction was Longboard Pharmaceuticals, Inc. Common Stock, cutting an estimated $21.4M.
  • Ikarian Capital fully exited argenx in Q1 2024, selling an estimated $26.5M.
  • Ikarian Capital's ten largest holdings make up 36% of its $912M portfolio in Q1 2024.
  • Ikarian Capital opened 54 new positions and closed 53 in Q1 2024.
  • Ikarian Capital's portfolio value fell 15% quarter-over-quarter to $912M.

Based on Ikarian Capital's 13F filing for Q1 2024, filed 15 May 2024.